In This Section

Program

Please Note: All session times for the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research – Translating Knowledge into Practice are U.S. Eastern Time (ET).

Saturday, February 5, 2022

Opening Keynote Session

Sunday, February 6, 2022

Plenary Session 1: Tumor Microenvironment
Plenary Session 2: Cancer Genomics and Cancer Evolution
Plenary Session 3: Cancer Immunology

Monday, February 7, 2022

Plenary Session 4: Cancer Immunotherapy
Plenary Session 5: Preclinical Models; Organoids; Genetic and Transplantation Models
Plenary Session 6: Epigenetics; Cancer Plasticity and Heterogeneity; RNA Networks

Tuesday, February 8, 2022

Plenary Session 7: Cancer Metabolomics
Plenary Session 8: Genome Instability
Plenary Session 9: Genetic and Environmental Factors in Carcinogenesis

Wednesday, February 9, 2022

Plenary Session 10: Early Detection of Cancer
Plenary Session 11: Drug Resistance
Plenary Session 12: New Technologies for Cancer Imaging and Other Emerging Technologies


Saturday, February 5, 2022

Opening Keynote session
6:30-8:30 p.m.

Reprogramming T Cells with CRISPR to enhance immunotherapy
Alexander Marson, University of California San Francisco, San Francisco, California

H. pylori infection, BRCAness, and gastric cancer
Masanori Hatakeyama, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan

Opening Reception
8-9:30 p.m.

Sunday, February 6, 2022

Continental Breakfast and Networking Roundtables
7-8 a.m.
Plenary Session 1: Tumor Microenvironment
8-9:30 a.m.

The aging microenvironment and its impact on tumor progression
Ashani T. Weeraratna, Johns Hopkins University, Baltimore, Maryland

The role and mechanism of SASP in tumor microenvironment of obesity-associated liver cancer
Naoko Ohtani, Osaka City University Graduate School of Medicine, Osaka, Japan

Mechanisms of neutrophil immune response in the bone metastatic prostate cancer
Leah M. Cook, University of Nebraska Medical Center, Omaha, Nebraska

Break
9:30-10 a.m.
Plenary Session 2: Cancer Genomics and Cancer Evolution
10-11:30 a.m.

Genotype to phenotype mapping of tumorigenesis at single cell resolution
Christina Curtis, Stanford University, Stanford, California

Genetic basis of pediatric cancers
Junko Takita, Kyoto University, Graduate School of Medicine, Kyoto, Japan

Translating cancer evolutionary insights into clinical practice
Mariam Jamal Hanjani, University College London Cancer Institute, London, United Kingdom

Free Time
11:30 a.m.-4:00 p.m.
Plenary Session 3: Cancer Immunology
4-5:30 p.m.

Title to be announced
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, New York

Regeneration of cytotoxic T lymphocytes from iPS cells: Development of “off-the-shelf T cells” for cell therapy targeting cancer and viral infection
Hiroshi Kawamoto, Kyoto University, Kyoto, Japan

Chimeric antigen receptors targeting of truncated O-glycopeptides
Avery D. Posey, Jr., University of Pennsylvania, Philadelphia, Pennsylvania

poster session A
5:30-7:30 p.m.

Monday, February 7, 2022

Continental Breakfast and Networking Roundtables
7-8 a.m.
Plenary Session 4: Cancer Immunotherapy
8-9:30 a.m.

When cancer cells enable an antitumor immune response
Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

Title to be announced
Hiroyoshi Nishikawa, National Cancer Center, Tokyo, Japan

Clonal evolution in a tumor microenvironment
Yosuke Togashi, Chiba Cancer Center, Kashiwa, Japan

Break
9:30-10 a.m.
Plenary Session 5: Preclinical Models; Organoids; Genetic and Transplantation Models
10-11:30 a.m.

Modeling pancreatic cancer
David A. Tuveson, Cold Spring Harbor Laboratory Cancer Center; Lustgarten Foundation, Cold Spring Harbor, New York

Malignant subclone drives polyclonal metastasis of intestinal tumor-derived organoids
Masanobu Oshima, Kanazawa University, Kanazawa, Japan

Additional speaker to be announced

free time
11:30 a.m.-4 p.m.
Plenary Session 6: Epigenetics; Cancer Plasticity and Heterogeneity; RNA Networks
4-5:30 p.m.

Biomolecular condensates produce new therapeutic hypotheses for cancer
Richard A. Young, Whitehead Institute, Cambridge, Massachusetts

Essential role of histone acetyltransferase TIP60 in acute myeloid leukemia
Issay Kitabayashi, National Cancer Center Research Institute, Tokyo, Japan

Chromatin structure dysregulated by aberrant splicing of BRD9 in cancer
Daichi Inoue, Institute of Biomedical Research and Innovation, Kobe, Japan

poster session b
5:30-7:30 p.m.

Tuesday, February 8, 2022

Continental Breakfast and Networking Roundtables
7-8 a.m.
PLENARY SESSION 7: CANCER METABOLOMICS
8-9:30 a.m.

Modulation of serine metabolism for cancer therapy
Karen H. Vousden, The Francis Crick Institute, London, United Kingdom

Targeting cancer NAD dependence
Nobuhiro Tanuma, Miyagi Cancer Center, Miyagi, Japan

Cancer metabolism within the tumor microenvironments
Tsuyoshi Osawa, The University of Tokyo, Tokyo, Japan

break
9:30-10 a.m.
PLENARY SESSION 8: GENOMIC INSTABILITY
10-11:30 a.m.

Extrachromosomal DNA (ecDNA): Cancer’s dynamic circular genome
Paul S. Mischel, Stanford University, Stanford, California

The labile control of mitotic chromosome segregation underlies chromosomal instability in cancer cells
Toru Hirota, The Cancer Institute Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan

Maintenance of genome integrity by BRCA1 tumor suppressor
Natsuko Chiba, Tohoku University, Miyagi, Japan

free time
11:30 a.m.-4 p.m.
Plenary Session 9: Genetic and Environmental Factors in Carcinogenesis
4-5:30 p.m.

Title to be announced
Olufunmilayo I. Olopade, UChicago Medicine Comprehensive Cancer Center, Chicago, Illinois

Allele – environment interplay in Asian gastric cancer
Shumpei Ishikawa, The University of Tokyo, Tokyo, Japan

Comprehensive analyses of genome and DNA adducts elucidate association between environmental factors and human cancer development
Yukari Totsuka, National Cancer Center, Tokyo, Japan

Poster session c
5:30-7:30 p.m.

Wednesday, February 9, 2022

Continental Breakfast and Networking Roundtables
7-8 a.m.
Plenary Session 10: Early Detection of Cancer
8-9:30 a.m.

Fecal and tissue DNA for diagnosis and prognosis of colorectal cancer
John M. Carethers, University of Michigan, Ann Arbor, Michigan

Early detection of gastric cancer by novel molecular serum biomarkers
Khay Guan Yeoh, National University of Singapore (NUS), Singapore, Singapore

Exosomal proteins in cancer: Roles in cancer metastasis and biomarker potential
Ayuko Hoshino, Tokyo Institute of Technology, Tokyo, Japan

break
9:30-10 a.m.
Plenary Session 11: Drug Resistance
10-11:30 a.m.

Mechanisms of resistance to systemic therapies in lung cancer
Katerina Politi, Yale Cancer Center, New Haven, Connecticut

Whole-animal approaches using Drosophila to develop novel therapeutic candidates for cancer treatment
Masahiro Sonoshita, Hokkaido University, Hokkaido, Japan

Exploring the link between replication stress and BRAF inhibitor resistance in melanoma
Patricia A. Possik, Brazilian National Cancer Institute, Rio de Janerio, Brazil

Free time
11:30 a.m.-4 p.m.
Plenary Session 12: New Technologies for Cancer Imaging and Other Emerging Technologies
4-5:30 p.m.

Visualizing immune responses using immunoPET
Anna M. Wu, City of Hope, Duarte, California

Applications of real-time fluorescence imaging for better operative outcomes after cancer surgery
Takeaki Ishizawa, The University of Tokyo, Tokyo, Japan

Molecular imaging of receptor membrane dynamics to reverse drug resistance in cancer
Patricia Ribeiro Pereira, Washington University School of Medicine, St. Louis, Missouri

poster session d
5:30-7:30 p.m.